Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. The appointments are part of the company's preparation for a planned U.S. securities exchange listing and advancement of L-DOS47, its lead antibody-enzyme conjugate, into the LDOS007 Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC).
“The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”
Mehrling highlighted the company's progress on its capital markets roadmap, noting the preparation of a base shelf prospectus and completion of auditor review of second-quarter financials. “Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution. Together, they significantly strengthen our ability to deliver on our clinical, corporate and capital markets objectives.”
Helen Middleton, BPharm, LPC, brings more than 30 years of experience across pharmacy, law, and the global life sciences industry. A qualified life sciences lawyer and registered clinical pharmacist, she has advised companies including Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. Most recently, she served as Legal Consultant to Kyowa Kirin International. As General Counsel, Middleton will oversee legal affairs, governance, compliance, and strategic transactions.
David Browning, MBA, brings more than 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, and academic sectors. He has overseen more than 30 Phase I-III clinical studies, spanning first-in-human through regulatory approval, and has built global oncology clinical operations teams across North America, Europe, Latin America, South Africa, and Asia-Pacific. As Vice President of Clinical Operations, Browning will lead operational planning and execution of Helix’s clinical programs, including LDOS007.
Helix BioPharma is an oncology company focused on developing Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances pre-IND candidates LEUMUNA™ and GEMCEDA™. For more information, visit https://www.helixbiopharma.com/.
